51P The development of a predictive model for risk results of the 70-gene signature

Abstract

Multigene signatures (MGS) select women with oestrogen receptor positive human epidermal growth factor receptor 2 negative (ER+/HER2-) breast cancer for whom adjuvant chemotherapy can be avoided. As MGS are expensive and require additional test material and time, models based on clinical-pathological features have been developed, mainly for OncotypeDX® but none exist for MammaPrint® (MP). We evaluated these models and the possibility of creating a new model for MP high/low genomic risk result.